BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland
21 févr. 2019 06h00 HE
|
BrainStorm Cell Therapeutics Inc.
ZURICH, Switzerland and NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly...
BrainStorm Issues a Statement to Patients and Shareholders
19 févr. 2019 08h06 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposium
04 févr. 2019 08h22 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida
25 janv. 2019 07h15 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Jan. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
BrainStorm Granted Additional Patent for NurOwn® in Israel
22 janv. 2019 08h40 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Jan. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for debilitating neurodegenerative...
BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA
11 janv. 2019 00h05 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK and IRVINE, Calif., Jan. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly...
BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week
03 janv. 2019 06h04 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that...
BrainStorm Issues 2018 Letter to Shareholders
27 déc. 2018 07h35 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Dec. 27, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a...
BrainStorm Expands Manufacturing of NurOwn® for Phase 2 Progressive MS Trial
26 déc. 2018 01h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK and BOSTON, Dec. 26, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced...
FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive Multiple Sclerosis
17 déc. 2018 07h34 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating...